What is he best known for?
The fields of study Joseph M. Connors is best known for:
His Lymphoma study frequently draws connections to adjacent fields such as Hodgkin lymphoma.
His Hodgkin lymphoma study frequently involves adjacent topics like Internal medicine.
His research is interdisciplinary, bridging the disciplines of Follicular lymphoma and Internal medicine.
He performs multidisciplinary study in Follicular lymphoma and Lymphoma in his work.
By researching both Oncology and Gastroenterology, he produces research that crosses academic boundaries.
Borrowing concepts from Oncology, he weaves in ideas under Gastroenterology.
In his research, he performs multidisciplinary study on Diffuse large B-cell lymphoma and International Prognostic Index.
Joseph M. Connors performs integrative International Prognostic Index and Diffuse large B-cell lymphoma research in his work.
By researching both Cancer research and Genetics, he produces research that crosses academic boundaries.
His most cited work include:
- Revised Response Criteria for Malignant Lymphoma (3812 citations)
- Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray (3384 citations)
- The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma (3357 citations)
What are the main themes of his work throughout his whole career to date
Joseph M. Connors integrates many fields in his works, including Lymphoma and Follicular lymphoma.
His Follicular lymphoma study frequently intersects with other fields, such as Internal medicine.
His research brings together the fields of Vinblastine and Internal medicine.
In his research, he performs multidisciplinary study on Oncology and Gastroenterology.
While working on this project, Joseph M. Connors studies both Gastroenterology and Oncology.
In his papers, he integrates diverse fields, such as Chemotherapy and Rituximab.
With his scientific publications, his incorporates both Rituximab and Chemotherapy.
While working on this project, Joseph M. Connors studies both Immunology and Antibody.
Joseph M. Connors connects Antibody with Immunology in his research.
Joseph M. Connors most often published in these fields:
- Lymphoma (87.54%)
- Internal medicine (75.70%)
- Oncology (58.26%)
What were the highlights of his more recent work (between 2019-2022)?
- Lymphoma (100.00%)
- Internal medicine (80.00%)
- Oncology (65.00%)
In recent works Joseph M. Connors was focusing on the following fields of study:
Phenotype and Mutation are the subject areas of his Gene study.
Joseph M. Connors performs multidisciplinary study in the fields of Mutation and Gene via his papers.
By researching both Lymphoma and International Prognostic Index, he produces research that crosses academic boundaries.
His Internal medicine study frequently links to adjacent areas such as Neutropenia.
In his articles, he combines various disciplines, including Neutropenia and Chemotherapy.
He performs integrative Chemotherapy and Progression-free survival research in his work.
Joseph M. Connors combines Oncology and Gastroenterology in his research.
In his study, he carries out multidisciplinary Gastroenterology and Oncology research.
Joseph M. Connors integrates Cyclophosphamide and Rituximab in his studies.
Between 2019 and 2022, his most popular works were:
- Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial (57 citations)
- Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma (41 citations)
- TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma (39 citations)
In his most recent research, the most cited works focused on:
- Chemotherapy
- Vincristine
- Brentuximab vedotin
Lymphoma is closely attributed to Hodgkin lymphoma in his work.
He regularly links together related areas like Lymphoma in his Hodgkin lymphoma studies.
He conducts interdisciplinary study in the fields of Chemotherapy and CD20 through his research.
In his works, Joseph M. Connors undertakes multidisciplinary study on CD20 and Chemotherapy.
He integrates Cyclophosphamide and Dacarbazine in his studies.
In his papers, he integrates diverse fields, such as Dacarbazine and ABVD.
While working on this project, he studies both ABVD and Vinblastine.
He integrates several fields in his works, including Vinblastine and Hodgkin's lymphoma.
In his papers, he integrates diverse fields, such as Hodgkin's lymphoma and Bleomycin.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
